Standard Neoadjuvant Therapy is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Pengfei Qiu (1). The most-studied condition is Breast Cancer Early Stage Breast Cancer (Stage 1-3).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer
NCT07269691 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer
|
Phase 3 | Not yet open | Pengfei Qiu | China |
|
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
NCT07257380 · ClinicalTrials.gov ↗ · Gastric / Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | Not yet open | Shanghai Zhongshan Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Pengfei Qiu | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Standard Neoadjuvant Therapy as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Pengfei Qiu (1) and Shanghai Zhongshan Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Standard Neoadjuvant Therapy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Standard Neoadjuvant Therapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Standard Neoadjuvant Therapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.